Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ScreenCancer scores exclusive deal for Quest's InSure FIT

This article was originally published in Clinica

Executive Summary

Norwegian cancer screening services provider ScreenCancer is to be the exclusive European distributor of InSure FIT, a "take-at-home" colorectal cancer screening test developed by Quest Diagnostics' subsidiary Enterix. The two-year deal will see Sandnes-based ScreenCancer offer the test to its customers in 24 European countries, including France, Germany and the UK. The InSure FIT (faecal immunochemical test) will be added to the panel of cancer screening products offered by ScreenCancer to privately-insured patients. The InSure FIT is designed for easy sample collection, which, in turn, will help increase patient compliance and enable early intervention. Unlike other FITs or faecal occult blood tests which require patients collect solid stool samples, the InSure FIT features a long-handled brush which is used to brush the surface of the stool. Only two samples are required for the InSure FIT and patients do not have to change their diets or medications during sample collection.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel